These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 36200096)

  • 1. Response to Pyrotinib in a Patient with Metastatic Bladder Urothelial Carcinoma Harboring HER2 V842I Mutation: A Case Report.
    Li S; Liu Q; Liu M; Liu T
    Cancer Manag Res; 2022; 14():2927-2932. PubMed ID: 36200096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human epidermal growth factor receptor 2-positive metastatic breast cancer with novel epidermal growth factor receptor -ZNF880 fusion and epidermal growth factor receptor E114K mutations effectively treated with pyrotinib: A case report.
    Yue L; Wentao L; Xin Z; Jingjing H; Xiaoyan Z; Na F; Tonghui M; Dalin L
    Medicine (Baltimore); 2020 Dec; 99(51):e23406. PubMed ID: 33371069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant.
    Gao Z; Xu J; Wang Y; Wu J; Sun T
    Front Oncol; 2021; 11():715554. PubMed ID: 34722261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial.
    Song Z; Li Y; Chen S; Ying S; Xu S; Huang J; Wu D; Lv D; Bei T; Liu S; Huang X; Xie C; Wu X; Fu J; Hua F; Wang W; Xu C; Gao C; Cai S; Lu S; Zhang Y
    BMC Med; 2022 Feb; 20(1):42. PubMed ID: 35101045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
    Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
    Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Ma F; Li Q; Chen S; Zhu W; Fan Y; Wang J; Luo Y; Xing P; Lan B; Li M; Yi Z; Cai R; Yuan P; Zhang P; Li Q; Xu B
    J Clin Oncol; 2017 Sep; 35(27):3105-3112. PubMed ID: 28498781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Case Report: Significant Efficacy of Pyrotinib in the Treatment of Extensive Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Cutaneous Metastases: A Report of Five Cases.
    Wang N; Li L; Xiong Y; Chi J; Liu X; Zhong C; Wang F; Gu Y
    Front Oncol; 2021; 11():729212. PubMed ID: 34976791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report.
    Yang ZY; Huang JH; Chen B; Xu CW; Lei L; Wang XJ; Fang MY
    Front Oncol; 2020; 10():559057. PubMed ID: 33123470
    [No Abstract]   [Full Text] [Related]  

  • 10. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report.
    Shan J; Ruan J; Tan Y; Yan L; Chen S; Du M; Wang L
    Onco Targets Ther; 2020; 13():9849-9856. PubMed ID: 33061462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pyrotinib in the treatment of advanced lung adenocarcinoma with HER2 exon 20 mutation: a case report and literature review.
    Luo Y; Yao B; Huang P; Zhao Y; Chen J
    Ann Palliat Med; 2021 Dec; 10(12):12906-12910. PubMed ID: 35016465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Pyrotinib in a Chinese Patient with Bone-Metastatic Scrotal Paget's Disease Harboring Triple Uncommon HER2 Mutation: A Case Report.
    Guo JJ; Jiao XD; Wu Y; Qin BD; Liu K; Zang YS
    Onco Targets Ther; 2020; 13():6289-6293. PubMed ID: 32753879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durable clinical benefit from pyrotinib combined with carboplatin in HER2-positive relapsed breast cancer previously treated with taxanes, anthracyclines, and trastuzumab.
    Zhu W; Wu J; Cui M; Zhang L
    Ann Palliat Med; 2020 Sep; 9(5):3684-3689. PubMed ID: 33065805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report.
    Wu J; You Y; Zhuang R; Guo X; Zhang C; Zhang Q; Zhou Y; Li Q
    Ann Transl Med; 2022 Mar; 10(6):387. PubMed ID: 35433993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pan-HER Tyrosine Kinase Inhibitor Pyrotinib Enhances Radiosensitivity via ERK1/2 Pathway in HER2-Positive Gastric Cancer.
    Niu Q; Liu J; Huang T; Su B; Zhang Y; Yuan X
    Oncol Res Treat; 2023; 46(1-2):11-25. PubMed ID: 36481773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete response to pyrotinib combined with letrozole as first-line treatment of HER2-positive/HR-positive breast cancer: a case report.
    Xie N; Liu L; Tian C; Hu Z; Ouyang Q
    Ann Transl Med; 2021 Aug; 9(16):1356. PubMed ID: 34532493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Analysis of the Efficacy and Safety of a Novel Irreversible HER2 Tyrosine Kinase Inhibitor Pyrotinib in Patients with HER2-Positive Metastatic Breast Cancer.
    Sun Y; Chen B; Li J; Peng L; Li S; Yu X; Li L
    Cancer Manag Res; 2021; 13():7165-7174. PubMed ID: 34548820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.
    Li Y; Qiu Y; Li H; Luo T; Li W; Wang H; Shao B; Wang B; Ge R
    Front Oncol; 2021; 11():664429. PubMed ID: 33996589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial Response to Pyrotinib Plus Capecitabine in an Advanced Breast Cancer Patient with
    Qu Y; Liu Y; Ding K; Li Y; Hong X; Zhang H
    Onco Targets Ther; 2021; 14():1581-1588. PubMed ID: 33688205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.